Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes
- PMID: 37314861
- PMCID: PMC10538421
- DOI: 10.1002/ana.26719
Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes
Abstract
Objective: Prior studies on the gut microbiome in Parkinson's disease (PD) have yielded conflicting results, and few studies have focused on prodromal (premotor) PD or used shotgun metagenomic profiling to assess microbial functional potential. We conducted a nested case-control study within 2 large epidemiological cohorts to examine the role of the gut microbiome in PD.
Methods: We profiled the fecal metagenomes of 420 participants in the Nurses' Health Study and the Health Professionals Follow-up Study with recent onset PD (N = 75), with features of prodromal PD (N = 101), controls with constipation (N = 113), and healthy controls (N = 131) to identify microbial taxonomic and functional features associated with PD and features suggestive of prodromal PD. Omnibus and feature-wise analyses identified bacterial species and pathways associated with prodromal and recently onset PD.
Results: We observed depletion of several strict anaerobes associated with reduced inflammation among participants with PD or features of prodromal PD. A microbiome-based classifier had moderate accuracy (area under the curve [AUC] = 0.76 for species and 0.74 for pathways) to discriminate between recently onset PD cases and controls. These taxonomic shifts corresponded with functional shifts indicative of carbohydrate source preference. Similar, but less marked, changes were observed in participants with features of prodromal PD, in both microbial features and functions.
Interpretation: PD and features of prodromal PD were associated with similar changes in the gut microbiome. These findings suggest that changes in the microbiome could represent novel biomarkers for the earliest phases of PD. ANN NEUROL 2023;94:486-501.
© 2023 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Conflict of interest statement
Potential Conflicts of Interest:
CH serves on the Scientific Advisory Board for Seres Therapeutics and Empress Therapeutics, who manufacture products that may be affected by this study. The remaining authors have nothing to report.
Figures
Comment in
-
Early microbiome changes in neurodegenerative disease.Nat Rev Neurol. 2023 Aug;19(8):458. doi: 10.1038/s41582-023-00848-5. Nat Rev Neurol. 2023. PMID: 37402802 No abstract available.
Similar articles
-
Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease.Ann Neurol. 2020 Aug;88(2):320-331. doi: 10.1002/ana.25788. Epub 2020 Jun 15. Ann Neurol. 2020. Retraction in: Ann Neurol. 2021 Aug;90(2):329. doi: 10.1002/ana.26151. PMID: 32441370 Retracted.
-
Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease.Mov Disord. 2024 Oct;39(10):1740-1751. doi: 10.1002/mds.29959. Epub 2024 Aug 28. Mov Disord. 2024. PMID: 39192744
-
Gut metagenomics-derived genes as potential biomarkers of Parkinson's disease.Brain. 2020 Aug 1;143(8):2474-2489. doi: 10.1093/brain/awaa201. Brain. 2020. PMID: 32844199
-
[The gut microbiome in Parkinson's disease].Nervenarzt. 2019 Feb;90(2):160-166. doi: 10.1007/s00115-018-0601-6. Nervenarzt. 2019. PMID: 30171304 Review. German.
-
Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.J Neurol. 2022 Mar;269(3):1154-1163. doi: 10.1007/s00415-021-10567-w. Epub 2021 Apr 21. J Neurol. 2022. PMID: 33881598 Review.
Cited by
-
Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease.Commun Med (Lond). 2024 Oct 23;4(1):209. doi: 10.1038/s43856-024-00630-8. Commun Med (Lond). 2024. PMID: 39443634 Free PMC article.
-
Infections in the Etiology of Parkinson's Disease and Synucleinopathies: A Renewed Perspective, Mechanistic Insights, and Therapeutic Implications.J Parkinsons Dis. 2024;14(7):1301-1329. doi: 10.3233/JPD-240195. J Parkinsons Dis. 2024. PMID: 39331109 Free PMC article. Review.
-
Concerns with the new biological research criteria for synucleinopathy.Lancet Neurol. 2024 Jul;23(7):663. doi: 10.1016/S1474-4422(24)00215-1. Lancet Neurol. 2024. PMID: 38876740 Free PMC article. No abstract available.
-
Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease.NPJ Parkinsons Dis. 2024 May 21;10(1):106. doi: 10.1038/s41531-024-00724-z. NPJ Parkinsons Dis. 2024. PMID: 38773112 Free PMC article.
-
Biomarkers for Managing Neurodegenerative Diseases.Biomolecules. 2024 Mar 26;14(4):398. doi: 10.3390/biom14040398. Biomolecules. 2024. PMID: 38672416 Free PMC article. Review.
References
-
- Kalia LV and Lang AE, Parkinson’s disease. Lancet, 2015. 386(9996): p. 896–912. - PubMed
-
- Dehay B, et al., Alpha-synuclein propagation: New insights from animal models. Mov Disord, 2016. 31(2): p. 161–8. - PubMed
-
- Holmqvist S, et al., Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol, 2014. 128(6): p. 805–20. - PubMed
-
- Svensson E, et al., Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol, 2015. 78(4): p. 522–9. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
